Change in Patent Law May Create “Blue” Gene Sequencers
Companies doing heavy-duty genetic research have sought to gain exclusive commercial rights to their work through patents. But patents in genes have proven controversial, prompting an op-ed from Michael Crighton in The New York Times and a vigorous online debate. Rep. Xavier Becerra (D-Cal.) has even introduced a federal bill, the “Genomic Research and Accessibility Act,” which would remove all patent protection for a “nucleotide sequence, or its functions or correlations, or the naturally occurring products it specifies.” As IP Law & Business reports, genetic researchers and their lobbyists are opposing the bill in Congress, and most experts believe the bill stands very little chance of passage.